Santen Pharmaceutical Co., Ltd. SNPHY
Set alert
11.82 USD +1.04 +9.65%
At close · Oct 30
11.82 Day range 11.82
9.22 52-week range 13.93
- YTD
- +14.76%
- 1 year
- +18.56%
- Open
- 11.82
- Prev close
- 10.78
- Mkt cap
- 3.80B
- Vol
- 4
- Avg vol
- 2.07K
- EPS
- 0.77
- P/E
- 15.35
More statistics
- Low
- 11.82
- High
- 11.82
6M chart
Events in this range
- May 11, 2026Earnings: 0.31; estimate —; surprise —%
- Sep 29, 2026Dividend: 0.10982
Signals (40)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 27, 2026 | 1 week ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 4 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 2 months ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
Newest 20 of 40.
Financial health
Altman Z-Score
5.31 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
8 / 9 Strong
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A4 / 5 overall
- DCF 4
- Return on Equity 4
- Return on Assets 5
- Debt / Equity 3
- P/E 3
- P/B 3
Valuation
P/E 14.5×
FY 2017 5y median 14.5× FY 2026
P/S 1.9×
FY 2017 5y median 1.7× FY 2026
P/B 1.9×
FY 2017 5y median 1.7× FY 2026
P/FCF 14.9×
FY 2017 5y median 14.9× FY 2026
EV/EBITDA 7.9×
FY 2017 5y median 8.2× FY 2026
EV/Sales 1.7×
FY 2017 5y median 1.5× FY 2026
FCF Yield 6.7%
FY 2017 5y median 6.7% FY 2026
Profitability
Gross Margin 55.2%
FY 2017 5y median 58.8% FY 2026
Operating Margin 15.5%
FY 2017 5y median 13.5% FY 2026
Net Margin 12.8%
FY 2017 5y median 10.2% FY 2026
ROE 13.3%
FY 2017 5y median 8.7% FY 2026
ROIC 11.2%
FY 2017 5y median 10.0% FY 2026
ROA 9.3%
FY 2017 5y median 6.1% FY 2026
Growth (YoY)
Revenue 3.1%
FY 2017 FY 2026
Operating Income 2.3%
FY 2017 FY 2026
EPS (diluted) 17.1%
FY 2017 FY 2026
Free Cash Flow -28.4%
FY 2017 FY 2026
Financial Health
Current Ratio 2.6×
FY 2017 5y median 2.5× FY 2026
Quick Ratio 1.9×
FY 2017 5y median 2.0× FY 2026
Debt / Equity 0.1×
FY 2017 5y median 0.1× FY 2026
Net Debt / EBITDA -0.7×
FY 2017 5y median -0.9× FY 2026
Interest Coverage 22.7×
FY 2017 5y median 17.3× FY 2026
Dividends
Dividend Yield 2.3%
FY 2017 5y median 2.4% FY 2026
Payout Ratio 33.8%
FY 2017 5y median 33.8% FY 2026
Annual · latest fiscal year ends 2026-03-31
